Azurity Pharmaceuticals, Inc., a private specialty pharmaceutical company, announced that the US Food and Drug Administration (FDA) approval of Fleqsuvy (baclofen oral suspension), 25 mg per 5 mL (5 mg/mL), concentrated formulation for the treatment of spasticity from multiple sclerosis (MS) or patients with spinal cord injuries and other spinal cord diseases.
